These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33566423)

  • 1. Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitory colitis. Authors' reply.
    Pai RK; Pai RK; Schaeffer DF; Choi WT; Kumarasinghe P; Brown I; Lauwers GY
    Aliment Pharmacol Ther; 2021 Mar; 53(5):638-639. PubMed ID: 33566423
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitor colitis.
    Buckle AD; Christensen B
    Aliment Pharmacol Ther; 2021 Mar; 53(5):636-637. PubMed ID: 33566405
    [No Abstract]   [Full Text] [Related]  

  • 3. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
    Dougan M
    Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: immune checkpoint inhibitor-induced colitis-shouldn't we be checking more often? Authors' reply.
    Wright AP; Piper MS; Bishu S; Stidham RW
    Aliment Pharmacol Ther; 2019 Sep; 50(5):613. PubMed ID: 31414534
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art.
    Le Saux O; Lounici Y; Wajda P; Barrin S; Caux C; Dubois B; Ray-Coquard I
    Crit Rev Oncol Hematol; 2021 Jan; 157():103172. PubMed ID: 33278676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy-Related Colitis: An Emerging Challenge and a Quest for Prospective Data.
    Kennedy LC; Grivas P
    JCO Oncol Pract; 2020 Aug; 16(8):464-465. PubMed ID: 32780983
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
    Casanova MJ; Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2021 Jul; 54(1):86-87. PubMed ID: 34109675
    [No Abstract]   [Full Text] [Related]  

  • 8. [Place of immunotherapy in digestive oncology].
    Saur A; Koessler T; Astaras C
    Rev Med Suisse; 2021 May; 17(739):979-984. PubMed ID: 34009757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy induced enterocolitis and gastritis - What to do and when?
    Cheung VTF; Brain O
    Best Pract Res Clin Gastroenterol; 2020; 48-49():101703. PubMed ID: 33317787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
    J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect.
    Du Y; Jin Y; Sun W; Fang J; Zheng J; Tian J
    Eur Radiol; 2019 Aug; 29(8):4294-4302. PubMed ID: 30506221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correspondence on 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten
    Ceccarelli F; Botticelli A; Gelibter AJ; Leccese I; Lucchetti R; Cortesi E; Valesini G; Marchetti P; Conti F
    Ann Rheum Dis; 2022 Jan; 81(1):e13. PubMed ID: 31907163
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: what can be done when infliximab stops working in ulcerative colitis? Authors' reply.
    Amiot A; Stefanescu C; Bouhnik Y
    Aliment Pharmacol Ther; 2016 Jan; 43(1):165. PubMed ID: 26638931
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):540-541. PubMed ID: 29341277
    [No Abstract]   [Full Text] [Related]  

  • 15. Body mass index: Another way to predict the efficacy of immune checkpoint inhibitors?
    Zheng SY; Cui HJ
    Int Immunopharmacol; 2020 Jul; 84():106523. PubMed ID: 32320929
    [No Abstract]   [Full Text] [Related]  

  • 16. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
    Bertani L; Pugliese D; Tricò D; Costa F; Blandizzi C
    Aliment Pharmacol Ther; 2021 Jan; 53(2):348-349. PubMed ID: 33368507
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune checkpoint inhibitors and timing of administration - Authors' reply.
    Qian DC; Buchwald ZS
    Lancet Oncol; 2022 Feb; 23(2):e57. PubMed ID: 35114126
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reply.
    Wang Z; Zhao Z; Wang J
    JAMA Oncol; 2020 Jul; 6(7):1116-1117. PubMed ID: 32352479
    [No Abstract]   [Full Text] [Related]  

  • 20. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
    Carlson RD; Flickinger JC; Snook AE
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.